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nor liver resections.  Conclusion: Although the majority of 
patients were young and had solitary metastasis, indications 
for liver resection are expanding as indicated by increasing 
numbers of elderly and patients with multiple liver metasta-
ses. Patients with non-colorectal liver metastases were sel-
dom candidates for resection.  © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Liver resection is considered standard treatment for 
patients with colorectal liver metastases (CRLM), with 
5-year overall survival rates of 50% or more, depending 
on several clinical risk factors  [1–3] . In addition, liver sur-
gery is accepted as a treatment option in patients with 
neuroendocrine liver metastases (NELM), with 5-year 
survival ranging from 60 to 80%  [4–6] . Selected patients 
with non-CRLM, non-NELM may also be potential can-
didates for surgical treatment, since several studies dem-
onstrated an association with improved survival after liv-
er resection  [7–12] .
 Improvements in anesthetic techniques and post-op-
erative care led to decreased mortality rates after liver sur-
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 Abstract 
 Objective: The study aims to evaluate all patients who un-
derwent liver resection for metastatic disease for demo-
graphics, characteristics of the primary tumor and metasta-
sis, volume of liver resection specimens per pathology labo-
ratory and to describe trends in surgical treatment.  Methods: 
Data were prospectively collected using the Dutch nation-
wide pathology network. All pathology reports containing 
details on liver resections for metastatic disease between 
January 2001 and December 2010 were evaluated.  Results: 
A total of 3,916 liver resections were performed in 3,699 pa-
tients with a median age of 63 years (range 1–91). The pri-
mary tumor was mainly colorectal (n = 3,256; 88.0%). The 
number of ‘high volume liver centers’ increased from 2 to 12 
in the study period, whereas the number of ‘low volume cen-
ters’ decreased. The number of liver resections increased 
from 224 to 596 per year (p  ≤ 0.0001). A significant increase 
was demonstrated in elderly patients, patients with multiple 
metastases, liver resections for smaller metastases and mi-
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gery of less than 3% in experienced liver surgery centers 
 [13–15] . With these improvements, indications for liver 
resection are expanding and more patients with liver me-
tastases undergo surgical treatment  [3, 16] . Besides peri-
operative management improvements, innovations in 
surgical and non-surgical techniques such as radio fre-
quent ablation (RFA) therapy, portal vein embolization 
and availability of effective neo-adjuvant systemic thera-
pies contribute to an increase in number of liver resec-
tions  [17, 18] . In patients with initially irresectable CRLM, 
pre-operative chemotherapy (often in combination with 
targeted agents such as bevacizumab and cetuximab) led 
to increased response rates and therefore to an increase 
of resectable CRLM  [19, 20] . All these factors are impor-
tant and might contribute to the growing number of liver 
resections.
 Population-based studies have described an increase 
in the amount of liver resections for metastatic disease, 
mainly in patients with colorectal cancer. In the UK, the 
number of patients who will undergo liver resection when 
diagnosed with CRLM increased from 1.7% in 1998 to 
3.8% in 2004  [21] . A similar French study reported an in-
crease in liver resection from 2 to 20% in the period be-
tween 1976 and 2000  [22] . In both studies, only patients 
with liver metastases from colorectal origin were evalu-
ated, and only few nationwide studies are available on liv-
er resections performed for non-CRLM  [8, 10, 12] .
 The aim of this study is to assess changes in the num-
ber of liver resections carried out in both patients with 
CRLM and non-CRLM. Different factors (e.g., number or 
size of metastases, patient age and tumor type) were eval-
uated during the study period to study potential differ-
ences in indication for liver surgery. Furthermore, the 
number of resection specimens per pathology laboratory 
was evaluated, in order to demonstrate the centralization 
of liver surgery.
 Methods 
 Patients and Data Collection 
 Data were collected using a query in the PALGA database. This 
nationwide network and registry of histopathology and cytopa-
thology in the Netherlands has been collecting pathology reports 
since 1971, with a nationwide coverage since 1991  [23] . The search 
terms ‘liver metastases’ and ‘histology’ were used in the PALGA 
database to identify all pathology reports containing details of liv-
er metastases between January 2001 and December 2010. Patients 
who underwent liver resection for a primary liver malignancy or a 
benign liver lesion were excluded from this study. When the origin 
of the primary tumor was not described in the pathology report, 
all pathology reports of that specific patient were critically re-
viewed in order to obtain the origin of the primary tumor. Both the 
privacy committee and scientific committee of PALGA approved 
the study design.
 The following characteristics were collected from the pathol-
ogy reports per patient: year of liver resection, age at time of 
resection, gender, location of the primary tumor, tumor type, 
number and size of the liver metastases and the completeness of 
the resection.
 Tumor typing was performed according to the International 
Classification of Diseases-10. Neuroendocrine carcinoma includ-
ed all types of neuroendocrine tumors (low and high grade). Pri-
mary tumors were classified according to the organ system of the 
primary tumor. Primary tumor location was classified as ‘not oth-
erwise specified’ (NOS), if no definite origin was reported.
 The type of liver resection was derived from the pathology re-
port. A minor resection was defined as a resection of 3 or less liver 
segments. A major resection was defined as a resection of more 
than 3 liver segments. A re-resection was considered to be a sched-
uled ‘2-stage procedure’ when patients underwent a re-resection 
within 3 months after the initial liver resection. These procedures 
were classified by definition as major resections.
 Liver resection was considered a complete resection (R0) when 
the pathologist described free resection margins. Details regarding 
distance of resection margins were not described in all pathology 
reports and therefore not recorded in the current study. The dif-
ference between microscopic incomplete (R1) and macroscopic 
incomplete resections (R2) was not always clearly reported, and 
therefore, both were analyzed as one group of incomplete resec-
tions. The size of the largest liver metastasis was reported in pa-
tients with multiple liver metastases.
 Pathology reports in the PALGA database are registered anon-
ymously, without details and names of the hospitals and surgeons, 
which delivered the resection specimen. The pathology laborato-
ries where the specimens were assessed were registered. Since all 
hospitals in the Netherlands where liver surgery is performed have 
their own pathology laboratory, the number laboratories is a reli-
able reflection of the number of hospitals. Laboratories that exam-
ine one or less liver resection specimen per year were defined as 
‘incidental’ centers. These centers were not included in the analysis 
of hospital volume. ‘Low volume centers’ were defined as labora-
tories that examine 2–9 liver resection specimens per year; labora-
tories that examine 10–19 liver resection specimens per year were 
defined as ‘middle volume’, and ‘high volume centers’ were de-
fined as laboratories that examine more than 20 liver resection 
specimens yearly.
 Statistics 
 The Mann–Whitney U test was used to compare medians be-
tween the group of patients with CRLM and the non-CRLM group. 
To compare nominal variables, the Pearson chi-square test was 
used. Multivariate logistic regression analyses were used to deter-
mine the independent effect of the time period of diagnosis on the 
chance to undergo liver resection. Stratification was carried out for 
size and number of metastases, type of resection and resection 
margins. Multivariate regression analyses were used to assess dif-
ferences in tumor and patient characteristics between ‘high’, ‘mid-
dle’ and ‘low volume centers’. A p value of <0.05 was considered 
statistically significant. All descriptive and statistical analyses were 
performed using Statistical Package for Social Sciences version 
18.0 (SPSS Inc., Chicago, Ill., USA).
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 Results 
 General Patient Characteristics 
 A total number of 24,138 pathology reports describing 
histologically confirmed liver metastases between 2001 
and 2010 were identified and reviewed from the PALGA 
database. The majority of these reports (n = 20,222) de-
scribed results of liver biopsies for metastatic disease and 
were excluded from the present study. The remaining 
3,916 pathology reports described liver resections for 
metastatic disease and were included in the present study. 
Resections were performed in 3,699 patients (59% men 
and 41% women). During the study period, 203 patients 
(5.5%) underwent a re-resection and 14 patients under-
went a third resection. Median age at the time of the pri-
mary liver resection was 63 years (range 1–91 years). The 
1-year-old patient underwent a liver resection for meta-
static Wilms tumor.
 Primary Tumor Characteristics 
 Most of the liver resections were performed in pa-
tients with metastatic carcinoma (n  = 3,557; 96.2%), 
mostly located in the colon or rectum (n = 3,238; 82.7%). 
Metastatic melanoma (n = 36; 1.0%) and metastatic sar-
coma (n = 46; 1.2%) were rare indications for liver resec-
tion (online suppl. table, see www.karger.com/
doi/10.1159/000441802). Other locations of carcinomas 
are presented in  table 1 . Tumor subtypes in CRLM from 
carcinoma were adenocarcinoma NOS (n = 3,224), neu-
roendocrine carcinoma (n = 11) and squamous cell car-
Table 1.  Primary tumor locations in patients with liver metastases from carcinoma who underwent liver resection
n  Sex, n (%) Age, years, 
median (range)m ale female
Head/neck
Total
Pharynx/larynx
Thymus
Thyroid gland
12 9 (75.0) 3 (25.0) 49 (17–65)
3 3 (100) – 56 (32–58)
2 2 (100) – 44 (35–52)
7 4 (57.1) 3 (42.9) 48 (17–65)
Digestive system
Total
Colon/rectum/appendix
Anus
Stomach
Esophagus
Gall bladder/biliary tract
Pancreas
Duodenum/small intestine
NOS
3,391 2,065 (60.9) 1,326 (39.1) 64 (24–94)
3,238 1,983 (61.2) 1,255 (38.8) 64 (24–94)
3 1 (33.3) 2 (66.7) 53 (45–59)
20 17 (85.0) 3 (15.0) 68 (36–79)
15 11 (73.3) 4 (26.7) 60 (35–73)
22 7 (27.3) 16 (72.7) 66 (52–86)
51 28 (54.9) 23 (45.1) 62 (34–82)
25 9 (36.0) 16 (64) 59 (45–75)
17 9 (52.9) 8 (47.1) 62 (38–86)
Lung 7 4 (57.1) 3 (42.9) 64 (52–76)
Skin 1 – 1 (100) 47
Breast 32 – 32 (100) 51 (31–82)
Genital tract
Total
Ovary
Uterus
Cervix
39 – 39 (100) 58 (28–85)
35 – 35 (100) 56 (28–85)
2 – 2 (100) 66 (61–71)
2 – 2 (100) 55 (51–58)
Urological tract
Total
Kidney
Urinary bladder
Prostate
Testis
33 21 (63.6) 12 (36.4) 58 (20–79)
26 15 (57.7) 11 (42.3) 65 (20–79)
4 3 (75.0) 1 (25.0) 68 (62–77)
1 1 (100) – 61 
2 2 (100) – 48 (27–68)
Adrenal 4 2 (50) 2 (50) 64 (59–68)
Other 2 1 (50) 1 (50) 64 (59–68)
NOS 36 12 (33.3) 24 (66.7) 62 (17–79)
Total 3,557 2,114 1,443
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cinoma (n = 3). The tumor type was not reported in 15 
patients with metastases from colorectal origin. In 3 pa-
tients, a GIST was diagnosed as the tumor subtype in 
liver metastases originating from a colorectal primary tu-
mor. Besides colon or rectum, other primary GIST loca-
tions were stomach (n = 7), duodenum or small intestine 
(n = 10) and digestive tract NOS (n = 1).
 Patients who underwent liver resection for non-
CRLM were younger at the time of operation (median 59 
years, range 1–86 years) compared to patients with 
CRLM (median 64 years, range 24–91 years; p  ≤ 0.0001). 
Patients with CRLM were predominantly men (61.4%), 
whereas patients who underwent resection for non-
CRLM were mostly women (58.1%; p  ≤ 0.0001). Female 
predominance in patients with non-CRLM can be ex-
plained by 52 patients (11.9%) with metastatic gyneco-
logical tumors (cervix n = 3; uterus n = 9, n = 3; and ova-
ry n = 40) and 32 patients (7.2%) with metastatic breast 
carcinoma.
 Liver Resections 
 Minor resections were performed in 2,336 patients 
(59.7%), mostly a segmentectomy (n = 1,483; 63.5%). A 
non-anatomical resection was performed in 834 patients 
(35.7%). In 19 patients (0.8%), the resection type was not 
specified. Hemihepatectomy was performed in 974 pa-
tients (24.9%), right-sided hemihepatectomy in 572 pa-
tients (14.6%), left sided hemihepatectomy in 171 pa-
tients (4.4%) and 117 patients (3.0%) underwent an ex-
tended hemihepatectomy. The side of the hepatectomy 
was not specified in 114 patients (2.9%).
 A complete resection (R0) was performed in 3,058 pa-
tients (78.1%), 482 patients (12.3%) underwent an in-
complete resection (R1 or R2), and in 376 patients (9.6%), 
the resection margins were not described. The median 
number of resected metastases was 1 (range 1–19) and the 
median size was 34.0 mm (range 1–280 mm).
 Re-Resections and ‘2-Stage Procedures’ 
 During the study period, 203 patients (5.5%) under-
went a re-resection, mostly for CRLM (n = 183; 95.3%). 
Eleven patients underwent a re-resection as part of an in-
tended ‘2-stage procedure’, after a median of 42 days 
(range 21–84 days) from the initial liver resection. The 
remaining 192 patients underwent a re-resection as a re-
sult of disease recurrence; 14 patients underwent a third 
liver resection. Patients who underwent a re-resection 
were significantly younger (median 61 years, range 24–78 
years) compared to patients who underwent a single liver 
resection (median 63 years, range 1–91 years; p = 0.042). 
The re-resection was performed after a median of 12 
months (range 3–73 months) from the initial liver resec-
tion.
 Liver Resections Per Pathology Laboratory 
 The number of pathology laboratories examining liver 
resection specimens decreased from 37 in 2001 to 31 in 
2010. Especially the ‘low volume’ and ‘sporadic centers’ 
decreased from 15 respectively 11 in 2001, to 10 respec-
tively 2 in 2010 ( fig. 1 ). A median of 28 resection speci-
mens (range 20–84) were evaluated annually in ‘high vol-
ume centers’. ‘Middle volume centers’ examined 13 resec-
tion specimens (range 10–19) per year, and in ‘low volume 
centers’, 4 resection specimens (range 2–9) were evalu-
ated yearly.
 In ‘high volume centers’, resection specimens with 
multiple metastases (OR 1.348, 95% CI 1.069–1.701) and 
non-CRLM (OR 1.397, 95% CI 1.216–3.452) were more 
often examined than in ‘middle’ and ‘low volume cen-
ters’. Furthermore, in ‘high volume centers’ patients were 
younger (<75 years) at the time of liver resection com-
pared to ‘low’ and ‘middle volume centers’ (OR 0.564, 
95% CI 0.423–0.754). No differences were observed in the 
amount of complete (R0) resections and in the size of the 
liver metastases between the ‘high’, ‘middle’ and ‘low vol-
ume centers’ ( table 2 ).
 Trends in Liver Resections 
 The annual number of liver resections increased from 
224 in 2001 to 596 in 2010 (p  ≤ 0.0001). This increase was 
mainly due to an increase in liver resections for CRLM. 
The number of liver resections performed for non-CRLM 
remained almost stable ( fig. 2 ). The percentage of re-re-
sections increased not significantly, from 3.9% in the pe-
riod between 2001 and 2004 to 5.0% between 2008 and 
2010.
 In 2001, the median age at the time of liver resection 
was 62 years (range 1–85 years), which increased to a me-
dian age of 64 years (range 28–89 years) in 2010 (p  ≤ 
0.0001). The higher age was also demonstrated by the per-
centage of elderly patients (>75 years) who underwent 
liver resection. Between 2001 and 2004, 9.1% of the pa-
tients undergoing a liver resection were older than 75 
years, which increased to 13.9% between 2008 and 2010 
(OR 1.61, 95% CI 1.25–2.07).
 Between 2001 and 2004, liver resections were mainly 
performed for solitary metastasis (67.2%), which de-
creased to 60.5% between 2008 and 2010. In this time pe-
riod, more liver resections were performed for multiple 
liver metastases (OR 1.34, 95% CI 1.13–1.58;  table 3 ).
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 During the study period, an increase in percentage of 
small metastases ( ≤ 50 mm) was demonstrated. In the pe-
riod between 2001 and 2004, 70.8% of the metastases were 
50 mm or smaller, which increased to 79.7% between 
2008 and 2010 (OR 1.62, 95% CI 1.27–2.07). This coin-
cided with an increase in minor resections from 63.5% 
between 2001 and 2004 to 74.7% between 2008 and 2010 
(OR 1.69, 95% CI 1.41–2.03;  table 3 ).
 Discussion 
 The current study describes all liver resections per-
formed in the last decade for metastatic disease in the 
Netherlands. A significant increase in number of liver re-
sections was demonstrated, predominantly in patients 
with CRLM. Part of this increase may be explained by the 
increasing incidence of primary colorectal carcinoma 
and, as a result, CRLM. Additional explanations for the 
increase in resections can be found in the expansion of 
indications for liver resection.
 A significant increase of patients’ age at the time of 
resection was demonstrated, as well as an increase in the 
percentage of elderly patients (>75 years). There is con-
troversy in the literature whether these elderly patients 
have an increased risk of postoperative complications 
and mortality. Some reports suggest that complication 
rates may be increased  [24] , whereas others report simi-
lar complication rates irrespective of age  [24–26] . The 
trend toward operating more elderly patients, as ob-
served in the current study, suggests that age is no longer 
considered a contraindication for liver resection. Data on 
comorbidity and clinical condition of the patient were 
not available in the current study, but these factors may 
very well be more important in judging patients fit for 
surgery.
0
Low volume
Middle volume
High volume
No. of
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 Fig. 1. Amount of liver resections per-
formed in high ( ≥ 20 liver resections per 
year), middle (10–19 liver resections per 
year) and low volume centers ( ≤ 1 liver re-
sections per year). Below the figure is the 
number of pathology (PA) laboratories in-
volved in examining liver resection speci-
mens per year. 
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Table 2.  Patterns in resection characteristics in low (1–9 liver resections per year), middle (10–19 liver resections 
per year) and high volume centers (≥20 liver resections per year) (logistic regression)
Low volume* 
(n = 390)
Middle volume 
(n = 723)
High volume 
(n = 2,629)
Size, mm
≤50
>50
NR
OR (≤50 vs. >50) (95% CI)
111 (75.5) 346 (82.0) 1,201 (76.4)
36 (24.5) 76 (18.0) 371 (23.6)
243 301 1,057
– 1.477 (0.941–2.317) 1.050 (0.708–1.556)
Number of metastases 
Solitary
Multiple
NR
OR (multiple vs. solitary) (95% CI)
251 (67.8) 443 (64.3) 1,549 (61.0)
119 (32.2) 246 (35.7) 990 (39.0)
20 34 90
– 1.171 (0.896–1.531) 1.348 (1.069–1.701)**
Resection margins
R0
R1/2
NR
OR (R1/2 vs. R0) (95% CI)
305 (87.1) 597 (90.3) 2,064 (85.6)
45 (12.9) 64 (9.7) 348 (14.4)
40 62 217
– 0.727 (0.484–1.090) 1.143 (0.819–1.594)
Type metastases
Colorectal
Non-colorectal
OR (CRLM vs. non-CRLM) (95% CI)
354 (90.8) 661 (91.4) 2,302 (87.6)
36 (9.2) 62 (8.6) 327 (12.4)
– 0.922 (0.600–1.419) 1.397 (1.216–3.452)**
Age, years
<75
≥75
OR (<75 vs. ≥75) (95% CI)
322 (82.6) 629 (87.0) 2,349 (89.3)
68 (17.4) 94 (13.0) 280 (10.7)
– 0.708 (0.504–0.994) 0.564 (0.423–0.754)
NR = Not reported. Values are n (%) unless otherwise indicated. * Low volume center was the reference for 
logistic regression; ** statistically significant with a p value <0.05.
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 Fig. 2. Number of liver resections per-
formed for metastatic disease.
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 The percentage of patients with multiple liver metas-
tases who underwent resection increased. Between 2001 
and 2004, only 32.8% of the liver resections were per-
formed for multiple metastases, which increased to 39.5% 
between 2008 and 2010. Until recently, surgery was usu-
ally only recommended for patients with up to 3 metas-
tases and no evidence of extrahepatic disease  [27] . A re-
cent meta-analysis reported no correlation between num-
ber of metastases and survival  [28] . Nowadays, multiple 
liver metastases are less often considered a contraindica-
tion because of the emergence of effective neo-adjuvant 
systemic therapy  [16] and improvements in surgical 
strategies. With combinations of portal vein emboliza-
tion  [29] , RFA therapies  [30] or 2-staged resections  [19, 
31] more patients become eligible for liver resection.
 Resected liver metastases were smaller in size in pa-
tients who underwent liver resection between 2008 and 
2010 compared to the size of metastases resected between 
2001 and 2004. Although data on neo-adjuvant systemic 
therapy were not available, increased neo-adjuvant treat-
ment may be a possible explanation for the smaller me-
tastases found in the resection specimens. Other explana-
tions could be improved imaging techniques or more rig-
orous follow-up schedules for patients suffering from 
colorectal cancer.
 In the present study, there were no differences in the 
percentages of complete resections (R0) between high 
and low volume centers. There were also no differences 
in the number of R0 resections in patients during the 
study period. Due to the nature of the study and many 
different pathology laboratories where the liver resection 
specimens were evaluated, it was impossible to discrimi-
nate between R1 and R2 resections. The exact free resec-
tion margin in millimeters was absent in many pathology 
reports; therefore, no definite conclusion could be drawn 
regarding exact resection margins.
 Although increasing numbers of patients in the 
 Netherlands undergo liver resection, still relatively few 
patients developing CRLM undergo liver surgery. Data 
from the national cancer registry show an incidence of 
colorectal carcinoma of 12,755 patients in 2010. In recent 
years 21–24% of patients with colorectal cancer presented 
with metastatic disease (M1) at the time of diagnosis, 
which is approximately 3,000 patients per year  [32–34] . 
These synchronous metastatic lesions are limited to the 
liver in approximately 55% of these patients (3,000 * 0.55 = 
Table 3.  Annual patterns in resection characteristics (logistic regression)
2001–2004* 2005–2007 2008–2010
Size, mm
≤50
>50
NR
OR (≤50 vs. >50) (95% CI)
364 (70.8) 526 (79.1) 798 (79.7)
150 (29.2) 139 (20.9) 203 (20.3)
547 573 616
– 1.559 (1.194–2.036)** 1.620 (1.268–2.069)**
Number of metastases 
Solitary
Multiple
NR
OR (multiple vs. solitary) (95% CI)
684 (67.2) 761 (63.9) 940 (60.5)
334 (32.8) 429 (36.1) 613 (39.5)
43 48 64
– 1.154 (0.968–1.377) 1.335 (1.132–1.576)**
Type of liver resection 
Minor
Major
NR
OR (major vs. minor) (95% CI)
540 (63.5) 730 (68.9) 1,066 (74.5)
314 (36.5) 332 (31.1) 367 (25.5)
207 176 184
– 1.279 (1.057–1.546)** 1.689 (1.407–2.028)**
Resection margins
R0
R1/2
NR
OR (R1/2 vs. R0) (95% CI)
796 (85.7) 966 (87.1) 1,296 (86.3)
133 (14.3) 143 (12.9) 206 (13.7)
132 129 115
0.886 (0.687–1.142) 0.951 (0.752–1.204)
 NR = Not reported. Values are n (%) unless otherwise indicated. * 2001–2004 was the reference period for 
logistic regression; ** statistically significant with p value <0.05. Note that all of the patients who underwent a 
2-staged procedure had multiple metastases and underwent a major resection.
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1,650 patients in Dutch population annually). Recent data 
from the national cancer registry demonstrated that ap-
proximately 20% of colorectal cancer patients will develop 
metastases during follow-up  [35] . This would be approx-
imately 1,900 colorectal patients in the total Dutch 
colorectal cancer population, and half of these patients 
would have metastases limited to the liver, which should 
be approximately 950 patients. Of these annual 2,600 pa-
tients with liver only disease (950 metachronous and 1,650 
synchronous), approximately 20% (498 patients with 
CRLM) underwent liver resection in 2010, according to 
the results of the present study. Although not all patients 
who develop liver only metastases will have resectable liv-
er metastases, the number of patients with CRLM who 
underwent liver resection in the Netherlands seems low. 
This is comparable to data from Morris et al.  [21] and 
Manfredi et al.  [22] , who reported similar data. A recent 
study from the Eindhoven Cancer Registry in the Nether-
lands reported all patients with stage IV primary colorec-
tal cancer and demonstrated that from 2004 to 2012 the 
number of patients who underwent liver surgery increased 
from 4 to 24%  [36] . This percentage may be a result of the 
decision-making process in management of patients with 
liver metastases. In the Netherlands, approximately 25 
hospitals are performing liver surgery, but colorectal sur-
gery is performed in almost all hospitals (>85 hospitals). 
When patients are diagnosed in these hospitals they are 
discussed in multidisciplinary teams, where a specialist 
liver surgeons is not always involved in these meetings. 
Also the presence of a dedicated medical oncologist is 
demonstrated to be important in considering patients 
suitable for neo-adjuvant chemotherapy in patients with 
CRLM  [37] . Jones et al.  [38] demonstrated that even in 
high-volume centers (UK cancer network), almost two-
thirds of patients with tumors who were deemed unre-
sectable by non-liver surgeons were considered potential-
ly resectable by a panel of specialist liver surgeons. On the 
other hand, there is also considerable inter-individual 
variation in the decision-making process between liver 
surgeons  [39] . This highlights the heterogeneity of onco-
logical liver surgery and emphasizes the importance of 
multidisciplinary liver tumor boards, to optimize the tim-
ing of surgical intervention and systemic treatment.
 Although approximately 20% of the patients with 
CRLM undergo resection, non-CRLM patients are only 
considered to be candidates for liver resection in highly 
selected cases  [10, 12] . The prevailing opinion that liver 
resection should not be considered as a curative option in 
non-CRLM patients may be insufficient, because 5-year 
disease-free survival after liver resection has been report-
ed  [10, 12, 40] . One of the reasons that non-CRLM pa-
tients might not be considered eligible for surgery is the 
fact that metastases are often diagnosed in an advanced 
disease stage, because imaging of the liver is not part of 
routine follow-up for many malignancies. Another rea-
son may be that patients with non-CRLM are often not 
exposed to liver surgeons. With the emergence of multi-
disciplinary tumor boards it may be assumed that sur-
geons take part in the decision making process concern-
ing the treatment of non-CRLM patients more often than 
in the past when this group of patients was mainly treated 
by medical oncologists.
 Centralization of complex upper gastrointestinal sur-
gery, especially liver surgery and the beneficial effect on 
outcome have been reported  [41] . Centralization of liver 
surgery in the Netherlands led to more ‘high volume’ and 
less ‘low volume’ and ‘sporadic centers’, as observed in the 
current study. Although it may be assumed that central-
ization of liver resections may have led to improved short- 
and long-term outcome, this could not be drawn from the 
present study, because follow-up data are lacking.
 In conclusion, the number of liver resections per-
formed for metastatic disease increased over the past de-
cade. Indications for liver resection seem to be expanding, 
reflected by the increasing percentage of elderly patients 
and the increasing amount of liver resections for multiple 
metastases. However, still only a minority of patients with 
liver metastases undergo liver resection. Therefore, we 
recommend that all patients with liver metastases 
(colorectal and non-CRLM) should be discussed in a 
multidisciplinary tumor board, including an expert liver 
surgeon, in order to offer the best possible treatment.
 Disclosure Statement 
None.
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